FDA Four-Month Delay Closes Kezar; Neurocrine Deal
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kezar Life Sciences was forced to close after a four-month FDA delay in scheduling a crucial meeting for its autoimmune hepatitis drug trial, according to STAT.
- Novo Nordisk's Wegovy pill and Eli Lilly's newly approved Foundayo are competing in the oral weight loss drug market, which Reuters projects to exceed $100 billion annually within the next decade.
- Seven obesity specialists interviewed by Reuters indicate strong patient demand for lower cost and greater convenience in new weight loss medicines, with many prescribing oral Wegovy to first-time GLP-1 users.
- Neurocrine Biosciences is set to acquire Soleno Therapeutics in a $2.9 billion deal, as reported by STAT News, indicating significant M&A activity in the biotech sector.
Why it matters: An FDA delay forced Kezar Life Sciences to close, impacting a potential treatment for autoimmune hepatitis.
